Abstract
Secnidazole is one of antiprotozoal medicines from the group of 5-nitroimidazoles, the method of HPLC with different types of detection is widely used for secnidazole determination. Aim. To develop the HPLC/UV-procedure of secnidazole quantification with application of the system of a “MiLiChrome® A-02” HPLC-analyzer and carry out the step-by-step validation of the procedure developed. Results and discussion. The specificity of the chromatographic conditions proposed was confirmed in relation to other medicines of the group of 5-nitroimidazoles (metronidazole, tinidazole, ornidazole and nimorazole). The retention time for secnidazole was 8.16 min. 0.01 M solution of hydrochloric acid was proposed for preparation of the reference and model solutions in developing the HPLC/UV-procedure of secnidazole quantification. To prove the possibility of application of the procedure proposed in further analysis its validation was carried out in the variants of the method of the calibration curve and the method of standard. Such validation parameters as in-process stability, linearity/calibration model, accuracy and precision (repeatability) were estimated using model solutions. Experimental part. The HPLC/UV analyses were performed using a MiLiChrome® A-02 high pressure liquid chromatograph (EcoNova, Russia). Eluent A (0.2 M LiClO4 – 0.005 M HClO4) and Eluent B (acetonitrile) were used as the mobile phase components. The HPLC microcolumn with the size of O2 × 75 mm and the ProntoSIL 120-5-C18 AQ reversed phase, 5 μm (BISCHOFF Analysentechnik und -gerate GmbH, Germany) was used as an analytical column. The analysis was performed at 40 °С and the flow rate of 100 μl/min. The mobile phase was run in the gradient elution mode, namely from 5 % to 100 % of Eluent B for 40 min, then 100 % of Eluent B for 3 min. Detection was performed at 277 nm. Conclusions. A new procedure of the secnidazole quantitative determination by the method of HPLC/UV has been developed. Its validation has been carried out, and acceptability for its application has been shown.
Highlights
The specificity of the chromatographic conditions proposed was confirmed in relation to other medicines of the group of 5-nitroimidazoles
The analysis was performed at 40 °С and the flow rate of 100 μl/min
The mobile phase was run in the gradient elution mode, namely from 5 % to 100 % of Eluent B for 40 min, 100 % of Eluent B for 3 min
Summary
The specificity of the chromatographic conditions proposed was confirmed in relation to other medicines of the group of 5-nitroimidazoles (metronidazole, tinidazole, ornidazole and nimorazole). 0.01 M solution of hydrochloric acid was proposed for preparation of the reference and model solutions in developing the HPLC/UV-procedure of secnidazole quantification. To prove the possibility of application of the procedure proposed in further analysis its validation was carried out in the variants of the method of the calibration curve and the method of standard. Such validation parameters as in-process stability, linearity/calibration model, accuracy and precision (repeatability) were estimated using model solutions
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have